Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma

NCT00740805 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

81

Enrollment

NIH

Sponsor class

Conditions

Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Solid Neoplasm

Interventions

DRUG: Cyclophosphamide
DRUG: Doxorubicin Hydrochloride
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Veliparib

Sponsor

National Cancer Institute (NCI)